ReviewJournal of thoracic disease2026
Lung transplantation in 2025: a narrative review of progress, challenges, and the road ahead.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Lung transplantation (LTx) remains the only definitive treatment for end-stage lung disease. Throughout 2025, the global transplant community has made notable progress in addressing persistent challenges in the field, ranging from policy-level improvements in graft allocation to deeper biological insights into post-transplant complications. This review aims to synthesize the pivotal literature published in 2025 across four core areas: optimizing allocation, advancing perioperative care, defining the mechanisms of graft injury, and exploring translational frontiers. Methods: We conducted a structured literature search focused primarily on studies published in 2025 that highlight major advancements in LTx. In addition, the search was supplemented with key society guidelines, consensus statements, and relevant early 2026 publications. Selected articles were critically analyzed and categorized into clinical advancements, and basic/translational findings. Key Content and Findings: In clinical research, the refinement of allocation strategies and the expansion of donor criteria, have effectively broadened access. Perioperative management has evolved with the integration of artificial intelligence to predict complications such as primary graft dysfunction (PGD) and chronic lung allograft dysfunction (CLAD). In basic and translational research, studies have dissected the molecular basis of complications. Additionally, new insights into the evolution of drug-resistant pathogens and macrophage plasticity have deepened our understanding of infection and rejection. Conclusions: In 2025, significant progress has been achieved in the field of LTx research. Strategies for clinical donor allocation and perioperative management, along with the understanding of molecular mechanisms underlying complications, have also been greatly improved. These advancements are essential to further optimize outcomes and address the complex challenges in LTx.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.